Sorafenib (BAY 43‐9006, Nexavar®), a Dual‐Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature
Author:
Publisher
Elsevier
Reference34 articles.
1. Kinase inhibition with BAY 43‐9006 in renal cell carcinoma;Ahmad;Clin. Cancer Res.,2004
2. CI‐1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK);Allen;Semin. Oncol.,2003
3. Dominant negative mutants of mitogen‐activated protein kinase pathway;Arboleda;Methods Enzymol.,2001
4. BRAF and RAS mutations in human lung cancer and melanoma;Brose;Cancer Res.,2002
5. Lack of BRAF mutation in primary uveal melanoma;Cohen;Invest. Ophthalmol. Vis. Sci.,2003
Cited by 395 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Resveratrol liposomes reverse sorafenib resistance in renal cell carcinoma models by modulating PI3K-AKT-mTOR and VHL-HIF signaling pathways;International Journal of Pharmaceutics: X;2024-12
2. Design, synthesis, in vitro, and in silico studies of new thiadiazol derivatives as promising VEGFR-2 inhibitors and apoptosis inducers;Journal of Molecular Structure;2024-11
3. Nature’s Elixir for Cancer Treatment: Targeting Tumor-induced Neovascularization;Current Medicinal Chemistry;2024-10
4. Integrated in silico and in vitro discovery of a new anticancer thiadiazole analog targeting VEGFR-2;Journal of Molecular Structure;2024-09
5. Sorafenib-Associated Bilateral Osteonecrosis of the Femoral Head;American Journal of Therapeutics;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3